xRead - September 2022

Wise et al.

Page 374

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

symptoms. nPIF: onset of action (3 hours) was shortest for BANS 256 μ g. Treatment efficacy

Study Year LOE Study design Study groups Clinical endpoint Conclusion Fokkens et al. 1283 group, multicenter PAR (n = 202, age 6–16 years). BANS 128 μ g daily vs placebo. group

BANS significantly more effective than placebo for nPIF, combined and individual nasal

symptom scores, and the overall evaluation of treatment efficacy. Onset of action within the first 12-hour time interval for combined nasal symptoms and within 48 hours for nPIF.

7–12 hours: BANS better than placebo in reducing combined nasal and blocked nose

was higher for those receiving BANS compared with placebo starting at 5 hours. All treatments well tolerated, no specific adverse events occurred.

Nasal symptom score lower with FPNS vs placebo. QOL significantly improved with

FPNS. Eosinophil count significantly lower in with FPNS.

Nasal congestion and subjective sleep improved significantly in the INCS-treated subjects but not in the placebo group.

BANS significantly decreased nasal symptoms vs FPNS. Both treatments significantly

decreased nasal symptoms vs placebo. Time to achieve statistically significant improvement: BANS 36 hours, FPNS 60 hours. Adverse events were mild and transient.

Nasal symptoms, QOL, and use of rescue medications were significantly better controlled in the regular-treated group as compared to the PRN group.

All 4 INCSs administered once daily were effective and well tolerated in the treatment of AR in adult patients, with similar efficacy and adverse event profiles. Based on sensory

attributes, patients preferred BANS and TANS vs MFNS and FPNS.

27% of PRN patients reported unsatisfactory control, worse QOL, and increased medication use. Patients who achieved satisfactory control in the PRN group had similar symptom and QOL scores to the regular group.

Daily nPIF, nasal symptom scores, and overall evaluation of treatment efficacy. Subset (n = 76) QOL by validated questionnaires.

Combined nasal score, individual nasal symptoms,

overall evaluation of treatment efficacy, nPIF.

Nasal symptom score, QOL, eosinophil count, and

eosinophilic cationic protein in nasal lavage.

Daily symptom diary of nasal symptoms, sleep, and daytime sleepiness.

Mean combined nasal symptoms scores (nasal blockage, runny nose, and sneezing).

Sneezing, stuffy nose, and rhinorrhea, measured by a daily diary. QOL questionnaires and rescue medication use (terfenadine).

Different endpoints for different studies

Daily symptoms and medication use, QOL, and patient satisfaction with symptom control.

SAR, ragweed-sensitivity (n = 217), symptoms for at least 1 year. Challenge via chamber. BANS 64 μ g vs BANS 256 μ g vs placebo. PAR (n = 20).

1 200 μ g aqueous beclomethasone dipropionate NS, twice daily, 1 week before until 1 week after the ragweed-pollen season (regular); 2 100 μ g of the spray, taken PRN, up to 400 μ g daily

Adults, SAR, ragweed sensitivity (n = 60). Beclomethasone dipropionate NS regular use (400 μ g daily) vs PRN use.

Adults, SAR, ragweed sensitivity (n = 52). FPNS PRN vs placebo for 4 weeks. Topical INCS vs placebo

Adults, PAR (n = 273). BANS and FNSP nasal sprays. Baseline: 8–14 days. 6 weeks: Active treatment.

Adults, SAR, ragweed sensitivity (n = 60). SAR and PAR.

14 studies reviewed. BANS, MFNS, FPNS, or TANS.

group.

placebo-controlled study

multicenter,

parallel-group

double-blind,

parallel-group

randomized, controlled,

comparison trials

blinded, parallel

group comparison

2002 1b RDBPCT, parallel

Day et al. 1282 2000 1b RDBPCT, parallel

Jen et al. 1288 2000 1b RDBPCT, parallel Day & Carrillo 1285

Craig et al. 707 1998 1b Double-blind,

1998 1b RDBPCT,

Juniper et al. 1286 1990 1b Randomized,

Herman 1273 2007 2a Review of

Juniper et al. 1287 1993 2b Randomized, non

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.